Mersana Therapeutics (NASDAQ:MRSN) Upgraded to Buy at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Mersana Therapeutics (NASDAQ:MRSN) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $4.50 price objective on the stock.

According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “

Separately, Cowen reiterated a buy rating on shares of G1 Therapeutics in a research note on Sunday, June 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Mersana Therapeutics currently has a consensus rating of Buy and an average target price of $21.50.

NASDAQ MRSN opened at $3.97 on Wednesday. Mersana Therapeutics has a 12 month low of $2.85 and a 12 month high of $17.32. The company has a current ratio of 6.24, a quick ratio of 6.24 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $4.19.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.73. Mersana Therapeutics had a negative net margin of 61.68% and a negative return on equity of 57.49%. The business had revenue of $41.04 million for the quarter, compared to analyst estimates of $30.11 million. Sell-side analysts predict that Mersana Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its position in Mersana Therapeutics by 46.2% in the fourth quarter. Rhumbline Advisers now owns 16,102 shares of the company’s stock worth $66,000 after buying an additional 5,090 shares during the last quarter. Algert Global LLC acquired a new position in Mersana Therapeutics in the first quarter worth approximately $110,000. Marshall Wace LLP acquired a new position in Mersana Therapeutics in the first quarter worth approximately $141,000. Bank of America Corp DE grew its position in Mersana Therapeutics by 1,409.6% in the fourth quarter. Bank of America Corp DE now owns 31,807 shares of the company’s stock worth $129,000 after buying an additional 29,700 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Mersana Therapeutics by 19.2% in the fourth quarter. Bank of New York Mellon Corp now owns 39,203 shares of the company’s stock worth $160,000 after buying an additional 6,306 shares during the last quarter. Hedge funds and other institutional investors own 77.40% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Read More: Bar Chart

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.